Status:
COMPLETED
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
Lead Sponsor:
Allergan
Conditions:
Alopecia
Alopecia, Androgenetic
Eligibility:
MALE
18-49 years
Phase:
PHASE2
Brief Summary
This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).
Eligibility Criteria
Inclusion
- Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year
- Willingness to maintain same hair style, length and hair color during study
- Willingness to have micro-dot-tattoo applied to scalp (Stage 2 only)
Exclusion
- Drug or alcohol abuse within 12 months
- HIV positive
- Received hair transplants or had scalp reductions
- Use of hair weaves, hair extensions or wigs within 3 months
- Use of minoxidil (oral or topical) and/or low level light treatment "combs" for hair growth within the last 6 months, or expected use during the study
- Application of topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to scalp within 4 weeks
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
244 Patients enrolled
Trial Details
Trial ID
NCT01904721
Start Date
August 1 2013
End Date
January 1 2015
Last Update
March 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fridley, Minnesota, United States